178 related articles for article (PubMed ID: 31817025)
1. TMPRSS4: A Novel Tumor Prognostic Indicator for the Stratification of Stage IA Tumors and a Liquid Biopsy Biomarker for NSCLC Patients.
Villalba M; Exposito F; Pajares MJ; Sainz C; Redrado M; Remirez A; Wistuba I; Behrens C; Jantus-Lewintre E; Camps C; Montuenga LM; Pio R; Lozano MD; de Andrea C; Calvo A
J Clin Med; 2019 Dec; 8(12):. PubMed ID: 31817025
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic alterations leading to TMPRSS4 promoter hypomethylation and protein overexpression predict poor prognosis in squamous lung cancer patients.
Villalba M; Diaz-Lagares A; Redrado M; de Aberasturi AL; Segura V; Bodegas ME; Pajares MJ; Pio R; Freire J; Gomez-Roman J; Montuenga LM; Esteller M; Sandoval J; Calvo A
Oncotarget; 2016 Apr; 7(16):22752-69. PubMed ID: 26989022
[TBL] [Abstract][Full Text] [Related]
3. DNA methylation analysis of tumor suppressor genes in liquid biopsy components of early stage NSCLC: a promising tool for early detection.
Markou Α; Londra D; Tserpeli V; Kollias Ι; Tsaroucha E; Vamvakaris I; Potaris K; Pateras I; Kotsakis Α; Georgoulias V; Lianidou Ε
Clin Epigenetics; 2022 May; 14(1):61. PubMed ID: 35538556
[TBL] [Abstract][Full Text] [Related]
4. Potential clinical utility of liquid biopsy in early-stage non-small cell lung cancer.
Shen H; Jin Y; Zhao H; Wu M; Zhang K; Wei Z; Wang X; Wang Z; Li Y; Yang F; Wang J; Chen K
BMC Med; 2022 Dec; 20(1):480. PubMed ID: 36514063
[TBL] [Abstract][Full Text] [Related]
5. Utility of TMPRSS4 as a Prognostic Biomarker and Potential Therapeutic Target in Patients with Gastric Cancer.
Tazawa H; Suzuki T; Saito A; Ishikawa A; Komo T; Sada H; Shimada N; Hadano N; Onoe T; Sudo T; Shimizu Y; Kuraoka K; Tashiro H
J Gastrointest Surg; 2022 Feb; 26(2):305-313. PubMed ID: 34379296
[TBL] [Abstract][Full Text] [Related]
6. Methylation-induced downregulation of TFPI-2 causes TMPRSS4 overexpression and contributes to oncogenesis in a subset of non-small-cell lung carcinoma.
Hamamoto J; Soejima K; Naoki K; Yasuda H; Hayashi Y; Yoda S; Nakayama S; Satomi R; Terai H; Ikemura S; Sato T; Arai D; Ishioka K; Ohgino K; Betsuyaku T
Cancer Sci; 2015 Jan; 106(1):34-42. PubMed ID: 25414083
[TBL] [Abstract][Full Text] [Related]
7. Identification of a novel synthetic lethal vulnerability in non-small cell lung cancer by co-targeting TMPRSS4 and DDR1.
Villalba M; Redin E; Exposito F; Pajares MJ; Sainz C; Hervas D; Guruceaga E; Diaz-Lagares A; Cirauqui C; Redrado M; Valencia K; de Andrea C; Jantus-Lewintre E; Camps C; Lopez-Lopez R; Lahoz A; Montuenga L; Pio R; Sandoval J; Calvo A
Sci Rep; 2019 Oct; 9(1):15400. PubMed ID: 31659178
[TBL] [Abstract][Full Text] [Related]
8. High expression level of TMPRSS4 predicts adverse outcomes of colorectal cancer patients.
Huang A; Zhou H; Zhao H; Quan Y; Feng B; Zheng M
Med Oncol; 2013 Dec; 30(4):712. PubMed ID: 24072509
[TBL] [Abstract][Full Text] [Related]
9. HOXA9 methylation and blood vessel invasion in FFPE tissues for prognostic stratification of stage I lung adenocarcinoma patients.
Lissa D; Ishigame T; Noro R; Tucker MJ; Bliskovsky V; Shema S; Beck JA; Bowman ED; Harris CC; Robles AI
Lung Cancer; 2018 Aug; 122():151-159. PubMed ID: 30032824
[TBL] [Abstract][Full Text] [Related]
10. Meta-analysis of comparing part-solid and pure-solid tumors in patients with clinical stage IA non-small-cell lung cancer in the eighth edition TNM classification.
Jiang T; Li M; Lin M; Zhao M; Zhan C; Feng M
Cancer Manag Res; 2019; 11():2951-2961. PubMed ID: 31114343
[No Abstract] [Full Text] [Related]
11. KMT2C promoter methylation in plasma-circulating tumor DNA is a prognostic biomarker in non-small cell lung cancer.
Mastoraki S; Balgkouranidou I; Tsaroucha E; Klinakis A; Georgoulias V; Lianidou E
Mol Oncol; 2021 Sep; 15(9):2412-2422. PubMed ID: 33159839
[TBL] [Abstract][Full Text] [Related]
12. Perioperative circulating tumor DNA as a potential prognostic marker for operable stage I to IIIA non-small cell lung cancer.
Li N; Wang BX; Li J; Shao Y; Li MT; Li JJ; Kuang PP; Liu Z; Sun TY; Wu HQ; Ou W; Wang SY
Cancer; 2022 Feb; 128(4):708-718. PubMed ID: 35076939
[TBL] [Abstract][Full Text] [Related]
13. High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients.
Ludovini V; Bianconi F; Siggillino A; Vannucci J; Baglivo S; Berti V; Tofanetti FR; Reda MS; Bellezza G; Mandarano M; Belladonna ML; Metro G; Chiari R; Sidoni A; Puma F; Minotti V; Roila F
Genes (Basel); 2021 Feb; 12(2):. PubMed ID: 33671892
[TBL] [Abstract][Full Text] [Related]
14. Monitoring with circulating tumor cells in the perioperative setting of patients with surgically treated stages I-IIIA NSCLC.
Garitaonaindia Y; Aguado-Noya R; Garcia-Grande A; Cordoba M; Coronado Albi MJ; Campo Cañaveral JL; Calvo V; Clemente MB; Álvarez R; Peñas M; Chara L; Royuela A; Provencio M
Transl Lung Cancer Res; 2023 Jul; 12(7):1414-1424. PubMed ID: 37577300
[TBL] [Abstract][Full Text] [Related]
15. The expression of TMPRSS4 and Erk1 correlates with metastasis and poor prognosis in Chinese patients with gastric cancer.
Luo ZY; Wang YY; Zhao ZS; Li B; Chen JF
PLoS One; 2013; 8(7):e70311. PubMed ID: 23922976
[TBL] [Abstract][Full Text] [Related]
16. Proposal on incorporating lymphovascular invasion as a T-descriptor for stage I lung cancer.
Wang S; Zhang B; Qian J; Qiao R; Xu J; Zhang L; Zhao Y; Zhang Y; Wang R; Zhao R; Han B
Lung Cancer; 2018 Nov; 125():245-252. PubMed ID: 30429028
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Effect of Lymphovascular Invasion on TNM Staging in Stage I Non-Small-cell Lung Cancer.
Noma D; Inamura K; Matsuura Y; Hirata Y; Nakajima T; Yamazaki H; Hirai Y; Ichinose J; Nakao M; Ninomiya H; Mun M; Nakagawa K; Masuda M; Ishikawa Y; Okumura S
Clin Lung Cancer; 2018 Jan; 19(1):e109-e122. PubMed ID: 29066222
[TBL] [Abstract][Full Text] [Related]
18. TMPRSS4 as an emerging potential poor prognostic factor for solid tumors: A systematic review and meta-analysis.
Zeng P; Zhang P; Zhou LN; Tang M; Shen YX; Jin J; Zhu YQ; Chen MB
Oncotarget; 2016 Nov; 7(46):76327-76336. PubMed ID: 27344186
[TBL] [Abstract][Full Text] [Related]
19. A prognostic DNA methylation signature for stage I non-small-cell lung cancer.
Sandoval J; Mendez-Gonzalez J; Nadal E; Chen G; Carmona FJ; Sayols S; Moran S; Heyn H; Vizoso M; Gomez A; Sanchez-Cespedes M; Assenov Y; Müller F; Bock C; Taron M; Mora J; Muscarella LA; Liloglou T; Davies M; Pollan M; Pajares MJ; Torre W; Montuenga LM; Brambilla E; Field JK; Roz L; Lo Iacono M; Scagliotti GV; Rosell R; Beer DG; Esteller M
J Clin Oncol; 2013 Nov; 31(32):4140-7. PubMed ID: 24081945
[TBL] [Abstract][Full Text] [Related]
20. A Panel of Novel Detection and Prognostic Methylated DNA Markers in Primary Non-Small Cell Lung Cancer and Serum DNA.
Ooki A; Maleki Z; Tsay JJ; Goparaju C; Brait M; Turaga N; Nam HS; Rom WN; Pass HI; Sidransky D; Guerrero-Preston R; Hoque MO
Clin Cancer Res; 2017 Nov; 23(22):7141-7152. PubMed ID: 28855354
[No Abstract] [Full Text] [Related]
[Next] [New Search]
